Characterization of a serum-free culture system comparing growth factor requirements of transformed and untransformed cells

Extracellular matrix analogs as carriers for growth factors: in vitro fibroblast behavior

Repair of connective tissue involves interactions between growth factors (GFs) and extracellular matrix (ECM) molecules. On the other hand, biological biomaterials could be used to carry and deliver GFs to stimulate wound healing. In the present study, fibroblasts were cultivated in a serum-free culture medium onto collagen (type I), hyaluronic acid, chondroitin sulfate, fibronectin, or fibrin. FGF, EGF, or PDGF was incorporated within those substrates. Using immuno- and radiolabeling assays, the distribution of GFs within the ECM analogs was relatively uniform and GFs retained in substrates were dependent on the substrates. Fibroblast replication was determined by the incorporation of [3H]-thymidine and compared to control groups. On collagen or chondroitin sulfate, the incorporation of GFs did not significantly improve cell proliferation. On hyaluronic acid, the incorporation of FGF and PDGF enhanced cell replication at 48 h. The incorporation of PDGF in fibronectin enhanced cell replication. On fibrin, the incorporation of PDGF, EGF, and FGF significantly enhanced cell replication. However, cell replication on FGF-incorporated fibrin was higher by 48 h than that on fibrin in the presence of FGF-supplemented culture medium. Fibrin sustains the biological activity of GFs, FGF in particular, and can be a carrier for GF that stimulates cell replication.

Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor. Variable effects of receptor-blocking antibody

Four human colon adenocarcinoma cell lines, SNU-C1, SNU-C4, SNU-C5, and NCI-H716, that are capable of proliferating autonomously in serum-free medium containing no added peptide growth factors were identified. All four cell lines show epidermal growth factor (EGF) receptors (EGFRs), express transforming growth factor alpha (TGF-alpha) messenger RNA, and release anti-TGF-alpha-immunoreactive molecules. The blocking anti-EGFR monoclonal antibody (mAb) 225 blocks autonomous proliferation of SNU-C1 and SNU-C4 cells. In both of these cell lines, the inhibitory effect of mAb 225 is reversible by the addition of EGF, TGF-alpha, or conditioned medium from any of the four cell lines. In contrast, autonomous proliferation of SNU-C5 and NCI-H716 cells is not inhibited by mAb 225 and is not affected by exogenous EGF, TGF-alpha, or conditioned medium. Together, these data confirm the previous finding that anti-EGFR antibodies can inhibit the proliferation of some carcinoma cell lines that coexpress TGF-alpha and EGFR. However, here it is shown that the mechanisms of autonomous proliferation of colon carcinoma cell lines are heterogeneous and not always sensitive to antibody disruption of TGF-alpha/EGFR autocrine interactions.

Evidence for c-myc in the signaling pathway for TGF-beta in well-differentiated human colon carcinoma cells

Previously, we described a model culture system for comparing responsiveness of poorly differentiated and well-differentiated human colon carcinoma cells to exogenous growth factors. While polypeptide growth stimulators elicited an up-regulation of c-myc, as well as a mitogenic response in the well-differentiated cells, the poorly differentiated cells were insensitive to exogenous growth stimulators. We now show, by thymidine incorporation experiments and autoradiographic analysis, that transforming growth factor beta 1 (TGF-beta) abrogated the mitogenic responses to the growth factors epidermal growth factor + insulin + transferrin (IC50 = 0.8 ng/ml), as well as to nutrients (basal medium; IC50 = 0.2 ng/ml) in the well-differentiated cells. The poorly differentiated cells did not respond to TGF-beta. Moreover, TGF-beta (10 ng/ml) completely abrogated the growth factor-stimulated up-regulation of c-myc in the TGF-beta responsive, well-differentiated colon carcinoma cells. Addition of TGF-beta to the TGF-beta-responsive, well-differentiated cells, at a time after c-myc had been transiently up-regulated in response to growth stimulatory factors, resulted in a loss of responsiveness to TGF-beta. Addition of TGF-beta to these cells at increasing time periods after EIT stimulation also resulted in a loss of the TGF-beta-induced repression of c-myc. The results suggest an important role for c-myc in the mechanism of action of TGF-beta in well-differentiated human colon carcinoma cells.